- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation of Microbiome Science into Health Solutions
Agreements with DayTwo, the Weizmann Institute of Science and Caelus Health Focus on Promoting Health through Microbiome Innovation
IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy
First therapy specifically indicated for this rare blood cancer; represents fifth indication for IMBRUVICA in the U.S.
Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)
Phase 1b/Phase 2 studies planned in multiple myeloma and solid tumors
Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen
Investigational Two-Drug Regimen of Rilpivirine and Dolutegravir Shows Efficacy As Maintenance Therapy in Patients Who Have Already Achieved Viral Suppression